Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3995095 | 0.84 | SMN1; SMN2 (0.52) | KMT2AGAAHSD17B10LMNAHPGD | |
| SCHEMBL177726 | 0.82 | NPSR1 (0.55) | KMT2ALMNAMEN1NPSR1GPR139 | |
| SCHEMBL1490845 | 0.81 | L3MBTL1 (0.61) | KMT2AGAAHPGDMEN1POLB | |
| SCHEMBL4552863 | 0.80 | ALDH1A1 (0.57) | KMT2AGAALMNAHPGDMEN1 | |
| SCHEMBL23665815 | 0.80 | KMT2A (0.64) | KMT2AGAAHSD17B10LMNAHPGD | |
| SCHEMBL177578 | 0.79 | SMN1; SMN2 (0.70) | KMT2AGAAHPGDMEN1 | |
| SCHEMBL190231 | 0.79 | HDAC8 (0.56) | KMT2AHPGDMEN1NPSR1KDM4E | |
| SCHEMBL161881 | 0.77 | KMT2A (0.81) | KMT2AGAAHSD17B10LMNAHPGD | |
| SCHEMBL161880 | 0.77 | GAA (0.81) | KMT2AGAAHSD17B10LMNAHPGD | |
| SCHEMBL1753831 | 0.77 | KMT2A (0.81) | KMT2AGAAHSD17B10LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020404-A1 | Cyanomethyl substituted N-Acyl Tryptamines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-04 | — | — | EP | disclosed |